Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 331.62%.

  • BioLineRx's EBITDA Margin fell 3029700.0% to 331.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.12%, marking a year-over-year decrease of 45400.0%. This contributed to the annual value of 4.89% for FY2024, which is 246100.0% up from last year.
  • Per BioLineRx's latest filing, its EBITDA Margin stood at 331.62% for Q3 2025, which was down 3029700.0% from 465.79% recorded in Q2 2025.
  • BioLineRx's 5-year EBITDA Margin high stood at 2010.59% for Q1 2025, and its period low was 1311.97% during Q1 2023.
  • For the 3-year period, BioLineRx's EBITDA Margin averaged around 39.28%, with its median value being 30.64% (2023).
  • Examining YoY changes over the last 5 years, BioLineRx's EBITDA Margin showed a top increase of 20207400bps in 2025 and a maximum decrease of -4395300bps in 2025.
  • Quarter analysis of 3 years shows BioLineRx's EBITDA Margin stood at 32.63% in 2023, then grew by 17bps to 27.13% in 2024, then crashed by -1123bps to 331.62% in 2025.
  • Its EBITDA Margin stands at 331.62% for Q3 2025, versus 465.79% for Q2 2025 and 2010.59% for Q1 2025.